APA (7th ed.) Citation

Sharma, R., Sharma, H., Jones, S., Borghini-Fuhrer, I., Domingo, G. J., Gibson, R. A., . . . Duparc, S. (2024). Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria. Malaria Journal, 23(1), 1. https://doi.org/10.1186/s12936-024-04924-z

Chicago Style (17th ed.) Citation

Sharma, Raman, et al. "Optimal Balance of Benefit Versus Risk for Tafenoquine in the Treatment of Plasmodium Vivax Malaria." Malaria Journal 23, no. 1 (2024): 1. https://doi.org/10.1186/s12936-024-04924-z.

MLA (9th ed.) Citation

Sharma, Raman, et al. "Optimal Balance of Benefit Versus Risk for Tafenoquine in the Treatment of Plasmodium Vivax Malaria." Malaria Journal, vol. 23, no. 1, 2024, p. 1, https://doi.org/10.1186/s12936-024-04924-z.